Profile data is unavailable for this security.
About the company
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
- Revenue in USD (TTM)41.28m
- Net income in USD-3.33m
- Incorporated1999
- Employees91.00
- LocationCumberland Pharmaceuticals Inc1600 West End Avenue, Suite 1300NASHVILLE 37203United StatesUSA
- Phone+1 (615) 255-0068
- Fax+1 (615) 255-0094
- Websitehttps://www.cumberlandpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MindWalk Holdings Corp | 14.97m | -22.72m | 52.76m | 102.00 | -- | 4.02 | -- | 3.53 | -0.6311 | -0.6128 | 0.3509 | 0.2812 | 0.4745 | 6.67 | 4.50 | -- | -72.01 | -32.32 | -90.53 | -36.45 | 58.50 | 55.79 | -151.78 | -100.97 | 4.09 | -23.68 | 0.17 | -- | 0.0082 | 11.77 | -11.25 | -- | 10.37 | -- |
| Nasus Pharma Ltd | 0.00 | -1.19m | 56.09m | -- | -- | -- | -- | -- | -0.1319 | -0.1383 | 0.00 | -0.4762 | 0.00 | -- | -- | -- | -373.32 | -- | -- | -- | -- | -- | -- | -- | -- | -2.51 | -- | -- | -- | -- | -54.23 | -- | -- | -- |
| ImmuCell Corp | 27.77m | 2.32m | 59.43m | 70.00 | 25.39 | 1.99 | 11.84 | 2.14 | 0.2588 | 0.2588 | 3.09 | 3.29 | 0.6159 | 1.90 | 11.42 | 402,453.60 | 5.15 | -5.35 | 5.69 | -5.77 | 40.93 | 36.02 | 8.37 | -11.87 | 1.76 | 6.47 | 0.2415 | -- | 51.64 | 14.06 | 62.65 | -- | -19.66 | -- |
| LifeVantage Corp | 210.05m | 7.86m | 59.49m | 232.00 | 7.75 | 1.80 | 5.52 | 0.2832 | 0.5998 | 0.5998 | 16.16 | 2.58 | 3.24 | 2.45 | 96.73 | 905,370.70 | 12.12 | 9.17 | 18.91 | 14.08 | 78.75 | 80.73 | 3.74 | 2.93 | 1.03 | -- | 0.00 | 35.06 | 14.17 | -0.3794 | 233.84 | -3.22 | -12.55 | -- |
| Janel Corp | 212.13m | 5.02m | 61.37m | 353.00 | 12.42 | 2.60 | 6.94 | 0.2893 | 4.17 | 4.17 | 175.99 | 19.89 | 1.48 | 32.91 | 3.83 | 600,929.20 | 3.97 | 1.76 | 13.95 | 5.33 | 32.04 | 26.69 | 2.69 | 0.9608 | 0.7095 | 3.62 | 0.5020 | 0.00 | 13.24 | 20.27 | 2,155.61 | -- | -14.58 | -- |
| Rafael Holdings Inc | 1.03m | -31.33m | 65.74m | 21.00 | -- | 0.781 | -- | 63.89 | -0.8471 | -0.8471 | 0.0284 | 1.63 | 0.0107 | -- | 3.35 | 49,000.00 | -32.33 | -45.03 | -37.62 | -51.75 | 89.70 | -- | -3,034.89 | -8,772.74 | 3.98 | -- | 0.0074 | -- | 43.96 | -28.51 | 11.30 | -- | -47.65 | -- |
| Scilex Holding Co | 40.36m | -375.84m | 69.71m | 30.00 | -- | -- | -- | 1.73 | -33.18 | -33.18 | 4.08 | -28.88 | 0.2145 | 7.27 | 1.85 | 350,956.50 | -177.73 | -- | -- | -- | 68.59 | 75.06 | -828.56 | -176.54 | 0.0429 | -3.76 | -- | -- | 21.07 | 21.89 | 56.40 | -- | -49.14 | -- |
| Cumberland Pharmaceuticals, Inc. | 41.28m | -3.33m | 73.59m | 91.00 | -- | 2.82 | 58.31 | 1.78 | -0.2331 | -0.2331 | 2.79 | 1.75 | 0.5788 | 1.72 | 3.80 | 453,608.30 | -4.68 | -6.88 | -7.60 | -9.65 | 84.49 | 80.74 | -8.09 | -15.89 | 1.11 | -28.41 | 0.1688 | -- | -4.26 | 1.95 | -3.19 | -- | -29.32 | -- |
| Assertio Holdings Inc | 137.35m | -28.92m | 74.82m | 58.00 | -- | 0.7072 | 33.90 | 0.5447 | -4.71 | -4.71 | 20.93 | 16.49 | 0.4611 | 1.35 | 1.47 | 2,368,138.00 | -9.71 | -15.74 | -17.07 | -24.19 | 68.16 | 82.29 | -21.06 | -42.01 | 1.43 | -- | 0.2702 | -- | -17.83 | -11.45 | 93.50 | -- | -- | -- |
| Pliant Therapeutics Inc | 0.00 | -175.50m | 79.88m | 171.00 | -- | 0.3988 | -- | -- | -2.87 | -2.87 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -48.60 | -38.70 | -52.81 | -41.26 | -- | -- | -- | -1,044.87 | -- | -- | 0.1319 | -- | -100.00 | -- | -30.35 | -- | 31.90 | -- |
| Polypid Ltd | 0.00 | -34.17m | 81.10m | 69.00 | -- | 7.05 | -- | -- | -2.26 | -2.26 | 0.00 | 0.6028 | 0.00 | -- | -- | 0.00 | -143.79 | -105.84 | -252.10 | -143.44 | -- | -- | -- | -- | 1.82 | -27.54 | 0.0826 | -- | -- | -- | -17.73 | -- | -23.10 | -- |
| Pelthos Therapeutics Inc | 7.41m | -23.58m | 85.29m | 4.00 | -- | 1.40 | -- | 11.52 | -17.09 | -17.09 | 6.02 | 18.85 | 0.1152 | -- | -- | 1,851,500.00 | -36.68 | -- | -47.05 | -- | 68.73 | -- | -318.41 | -- | 1.04 | -12.32 | 0.00 | -- | -- | -- | -7.78 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 30.83m | -26.01m | 87.46m | 71.00 | -- | -- | -- | 2.84 | -3.44 | -3.44 | 3.50 | -1.80 | 0.8352 | 1.09 | 8.75 | 434,211.30 | -70.48 | -71.91 | -217.79 | -111.91 | 91.36 | -- | -84.38 | -729.00 | 1.18 | -1.70 | 1.94 | -- | 47.66 | -- | -14.31 | -- | -47.58 | -- |
Data as of Mar 02 2026. Currency figures normalised to Cumberland Pharmaceuticals Inc's reporting currency: US Dollar USD
17.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ikarian Capital LLCas of 31 Dec 2025 | 555.93k | 3.72% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 472.16k | 3.16% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 366.16k | 2.45% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 341.09k | 2.28% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 253.51k | 1.70% |
| Bridgeway Capital Management LLCas of 31 Dec 2025 | 163.47k | 1.09% |
| Boothbay Fund Management LLCas of 31 Dec 2025 | 128.51k | 0.86% |
| Geode Capital Management LLCas of 31 Dec 2025 | 107.27k | 0.72% |
| J. Goldman & Co. LPas of 31 Dec 2025 | 94.54k | 0.63% |
| Newton Investment Management North America LLCas of 31 Dec 2025 | 71.84k | 0.48% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
